| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abiraterone |
08.03.04.02 |
Restricted Use
|
NICE TA259: Abiraterone for treating metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen |
| Acitretin |
13.05.02 |
Restricted Use
|
NICE CG153: Psoriasis - assessment and management |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severeley active ulcerative colitis after failure of conventional therapy |
| Adalimumab |
01.05.03 |
Restricted Use
|
TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA486 Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA486 Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA294 Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA346 Aflibercept for treating diabetic macular oedema |
| Alirocumab |
20.01 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Restricted Use
|
NICE guidelines - Alitretinoin for chronic eczema |
| Apixaban |
02.08.02 |
Formulary
|
NICE guidance: Apixaban for the prevention of VTE after total hip or knee replacement in adults |
| Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis |
| Brodalumab |
13.05.02 |
Formulary
|
NICE TA511 - Brodalumab for treating moderate to severe plaque psoriasis |
| Calcipotriol 50micrograms/g with Betamethasone 0.05% |
13.05.02 |
Formulary
|
NICE CG153: The assessment and management of psoriasis |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ciclosporin |
13.05.03 |
Formulary
|
NICE CG153: Psoriasis - assessment and management |
| Ciclosporin 1mg/mL Eye Drops |
11.08.01 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Colesevelam |
02.12 |
Restricted Use
|
NICE evidence review: Colesevelam for bile acid malabsorption |
| Collagenase clostridium histolyticum |
10.03.01 |
Formulary
|
NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA 327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for the treatment and secondary prevention of stroke and systemic embolism in atrial fibrilation |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dexamethasone |
11.04.02 |
Formulary
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Donepezil Hydrochloride |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Dulaglutide |
06.01.02.03 |
Formulary
|
NICE ESNM59: Dulaglutide for Type 2 Diabetes |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and preventing DVT and PE |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and embolism in people with non-valvular AF |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic perpura |
| Eluxadoline |
01.04.02 |
Restricted Use
|
NICE TA471 - Eluxadoline (Truberzi) for treating irritable bowel syndrome with diarrhoea in adults |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
| Etanercept |
13.05.03 |
Restricted Use
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
13.05.03 |
Restricted Use
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
10.01.03 |
Restricted Use
|
TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
10.01.03 |
Restricted Use
|
- TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etelcalcetide |
06.06.01 |
Restricted Use
|
NICE TA448 Etelcalcetide for treating secondary hyperparathyroidism |
| Evolocumab |
20.01 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Galantamine |
04.11 |
Restricted Use
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Galantamine |
04.11 |
Restricted Use
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis |
| Idelalisib 100mg and 150mg tablets |
20.01 |
Restricted Use
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severeley active ulcerative colitis after failure of conventional therapy |
| Ixekizumab 80mg solution for injection |
13.01 |
Formulary
|
NICE TA442 - Ixekizumab for treating moderate to severe plaque psoriasis |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506 Lesinurad for treating chronic hyperuricaemia in people with gout |
| Linaclotide |
01.06.07 |
Restricted Use
|
NICE ESNM16: Irritable bowel syndrome with constipation in adults: linaclotide |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE guidance 28 - Type 2 dibetes in adults: management |
| Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318 Lubiprostone for treating chronic idiopathic constipation |
| Memantine Hydrochloride |
04.11 |
Formulary
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Methotrexate |
13.05.03 |
Restricted Use
|
NICE CG153: Psoriasis - assessment and management |
| Naloxegol oxalate |
01.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid-induced constipation |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443 Obeticholic acid for treating primary biliary cholangitis |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278: Omalizumab for treating severe persistent asthma |
| Pemetrexed |
08.01.03 |
Formulary
|
TA190 (updated from June 2010) - Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
| Pomalidomide |
08.02.04 |
Restricted Use
|
NICE TA338: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib |
| Prucalopride |
01.06.07 |
Restricted Use
|
NICE TA211: Prucalopride for constipation in women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274 Ranibizumab for treating diabetic macular oedema |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479 Reslizumab for treating severe eosinophilic asthma |
| Rifaximin 550mg tablets |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE guidance: Rivaroxaban for the treatment of deep vein thrombosis and the prevention of recurrent DVT and PE |
| Rivastigmine |
04.11 |
Restricted Use
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Roflumilast |
03.03.03 |
Formulary
|
TA461 - Roflumilast for treating chronic obstructive pulmonary disease |
| Sacubitril/valsartan |
02.05.05.02 |
Formulary
|
TA 388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Sarilumab |
10.01.03 |
Restricted Use
|
NICE TA485 Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
20.01 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
20.01 |
Formulary
|
NICE TA350:Secukinumab for treating moderate to severe plaque psoriasis |
| Teriparatide |
06.06.01 |
Restricted Use
|
NICE TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518 - Tocilizumab for treating giant cell arteritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518 - Tocilizumab for treating giant cell arteritis |
| Tofacitinib |
10.01.03 |
Restricted Use
|
NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis |
| Tolvaptan |
06.05.02 |
Restricted Use
|
NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
TA458 - Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Formulary
|
- TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severley active ulcerative colitis |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
